Company intelligence / Profile preview

Cephalgo

Ownership: Private
Development stage: Preclinical

Overview

Cephalgo develops wearable and software solutions that use biosignal technology and advanced AI to monitor real-time emotional and mental states, provide personalized support recommendations, facilitate communication between individuals and professionals, and offer neurofeedback protocols for depression management. Their research includes accessible emotion analysis across demographics, brain-gut axis mapping for holistic care, and neurofeedback tools targeting depressive neural patterns.

Therapeutic areas: Psychiatry
Modalities: DeviceNon-pharmacological therapyAI-based digital therapeutic (inferred from context)
Industry: Digital Health Medical Devices

Beyond the preview

Go deeper on Cephalgo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cephalgo.

Explore the full profile